Intech Biopharm Corporation (TPEX:6461)

Market Cap	3.11B
Revenue (ttm)	39.78M
Net Income (ttm)	-368.21M
Shares Out	137.94M
EPS (ttm)	-2.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,144
Average Volume	96,337
Open	21.80
Previous Close	22.55
Day's Range	21.80 - 22.50
52-Week Range	20.90 - 34.60
Beta	0.34
RSI	20.01
Earnings Date	Mar 13, 2025

About Intech Biopharm

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 82
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6461

Financial Performance

In 2024, Intech Biopharm's revenue was 39.78 million, an increase of 53.90% compared to the previous year's 25.85 million. Losses were -368.21 million, 8.94% more than in 2023.